CI

At a glance

ClinicalIndex Comparison Record
Phase 1Completed· 19 enrolled
Drug / intervention
D6-25-hydroxyvitamin D3drug
Likely dose
Not stated in record
Structured eligibility isn't available for this trial yet — see the full criteria in the Eligibility tab below.

Standardized by ClinicalIndex from the ClinicalTrials.gov record · verify against the source.

Search/NCT03576716
NCT03576716Phase 1Completed
CompareCT.gov

Clearance of 25-hydroxyvitamin D3 During Vitamin D3 Supplementation

University of Washington·interventional·Posted Jul 3, 2018·Updated May 17, 2022

In Brief

A Phase 1 clinical trial evaluating D6-25-hydroxyvitamin D3 for Chronic Kidney Disease. Completed, enrolled 19 participants across 1 site.

Detailed Summary

The goal of this study is to determine how 25(OH)D3 clearance is affected by vitamin D3 supplementation using a gold standard pharmacokinetic approach.

Study Details

Study Typeinterventional
Allocation--
Masking--
Primary Purpose--
ConditionsChronic Kidney Disease
CountriesUnited States
CollaboratorsNational Institute of Diabetes and Digestive and Kidney Diseases (NIDDK)

Timeline

Phase 1CompletedFinished
20192020202120222023202420252026
First PostedJul 3, 2018
Enrollment StartJun 1, 2018
Primary CompletionJul 8, 2019
Study CompletionJan 1, 2021
TodayJul 2, 2026
Enrollment to primary: 1.1 yearsPosted 8.0 years ago

Interventions

D6-25-hydroxyvitamin D3drug

Intravenous administration of a deuterium-labeled 25(OH)D3 to evaluate the metabolic clearance of 25(OH)D3